- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. ... Read More
When multiple myeloma relapses,
Look to KYPROLIS®
for the way forward
A NEW KYPROLIS® regimen
DKd: KYPROLIS®+Darzalex® (daratumumab)+dexamethasone
KRd as a triplet therapy
KRd = KYPROLIS® (carfilzomib)+lenalidomide and dexamethasone; Kd = KYPROLIS®+dexamethasone; RRMM = relapsed or refractory multiple myeloma.